Purpose According to the American Cancer Society, 1 in 8 women in the U.S. will develop breast cancer, with triple-negative breast cancer (TNBC) comprising 15-20% of all breast cancer cases. TNBC is an aggressive subtype due to its high metastatic potential and lack of targeted therapy. Recently, folate receptor alpha (FRA) is found to be expressed on 80% of TNBC with high expression correlating with poor prognosis. In this study, we examined whether binding IgA 
Introduction
According to the American Cancer Society, approximately 1 in 8 women in the U.S. will develop breast cancer at some point in their life [1] . Of these women, 15-20% will be diagnosed with triple-negative breast cancer (TNBC), an aggressive subtype with a high mortality rate [2] . TNBC refers to breast tumors that lack receptors for estrogen (ER), progesterone (PR), and epidermal growth factor (HER2) and therefore, are not dependent on them for growth. These tumors do not respond to hormonal therapy (e.g., tamoxifen or aromatase inhibitors) or HER2-targeted therapy (e.g., trastuzumab). Of these women who are diagnosed with TNBC, approximately 23% will not survive 5 years [3] . Lack of effective targeted therapies forces clinicians to rely heavily on chemotherapeutics that nonspecifically target replicating cells, resulting in toxic side effects. The most promising targeted treatment for TNBC is olaparib (PARP inhibitor), approved this year for treating advanced breast cancers with BRCA mutations. However, this drug only targets TNBC patients who present with BRCA1/2 gene mutation (approximately 20%) [4] . Thus, there is a clear need for new drugs targeting TNBC, where an unmet need exists with limited targeted therapy approved.
Folate receptor type alpha (FRA) is over-expressed by a majority of cancers including breast, with limited expression in healthy tissue and organs [5, 6] . In normal tissue, FRA is mainly expressed on the luminal surface of epithelial cells, making it inaccessible via the vasculature, thus eliminating toxic side effects of FRA-targeted treatments. Recently, two studies found FRA expression to strongly associate with ER/PR-negative and TNBC (> 80%) status as well as poor prognosis with FRA expression associated with metastatic breast cancer and worse overall/ disease-free survival [7, 8] . Thus, FRA is an ideal target for directing therapeutic agents to TNBC. In fact, some folate conjugates, such as folatefluorescein or folate-IgG have shown significant anti-tumor activity in mice [9, 10] . Anti-FRA IgG antibodies such as MORAB-003 (Farletuzumab) have also been reported to target ovarian cancer and have been tested in patients [11] . However, this drug failed to show efficacy in Phase I/II trials. A recent study shows MORAB-003 decreased tumor growth of ovarian cells by inducing autophagy but not necessarily apoptosis [12] suggesting inhibition of FRA alone is not enough to kill tumor cells. MORAB-003 was shown to induce ADCC in vitro [13] . IgG antibodies stimulate ADCC through binding of their Fc portion to FcγIII receptors on leukocytes [14, 15] . However, ADCC response mediated through binding of IgG to FcγIII in vivo is weak due to low FcγIII levels, the presence of high competing serum IgG, the presence of FcγIII on non-cytotoxic cells, and the presence of inhibitory FcγII receptors [14, 16] . Thus, IgG monoclonal antibodies are unable to promote effective anti-tumor responses [17, 18] and, because of their large size, have poor tumor penetration [19] . FcαR1, on the other hand, is only expressed on cytotoxic cells and in high numbers on PMNs making this receptor a very potent IgA mediator of ADCC independent of cytokine co-factor(s) [20] .
In this study, we demonstrate novel binding of IgA Fcfolate conjugates to FRA-expressing TNBC cells. Upon binding, Fc-folate recruits and activates PMNs to destroy TNBC cells by binding FcαR1 on the PMN and activating ADCC (Fig. 1) . Numerous studies document PMNs as potent effector cells for IgA-mediated cellular cytoxicity [21] [22] [23] [24] [25] [26] [27] [28] . These findings suggest that an FRA-targeted therapy can effectively kill TNBC cells and may represent an effective, targeted treatment for TNBC.
Materials and methods

Reagents and cell culture
Human SUM TNBC cell lines were a kind gift from Dr. Stephen Ethier. All other TNBC cell lines (MDA-MB-231, MDA-MB-468, BT549) were purchased from ATCC. iGROV1 cells (shFRA and NS) were a kind gift from Dr. Larry Matherly. Sf9 and Hi-Five insect cells were purchased from Thermo Fisher Scientific (Waltham, MA) and grown in SF900 medium supplemented with 10% FBS and Express Five serum-free medium containing 20 mM glutamine, respectively. TNBC cell lines were authenticated via cytogenetic analysis or used within 6 months of purchase or stored in liquid nitrogen for future use. Cell culture reagents were purchased from Thermo Fisher Scientific. IgA from pooled human serum was purchased from Athens Research and Technology (Athens, GA). 
Isolation and labeling of PMN from whole blood
Heparin anti-coagulated blood was obtained from healthy volunteers after informed consent in accordance with ethical guidelines of Wayne State University. PMNs were isolated using Ficoll-Paque followed by dextran (1%) density gradient centrifugation as described previously [29] and labeled with 10 μg/ml BCECF-AM (ThermoFisher Scientific) for 30 min at 37 °C just before use.
Stable transduction of cells with FRA shRNA plasmids
Transduction reagents were purchased from ThermoFisher Scientific. GIPZ Lentiviral particles containing FRA shRNA #4 vector (shFRA) or non-silenced control vector (NS) were obtained from Karmanos Cancer Institute by subscription to Thermo Scientific GIPZ shRNAmir library. Lentiviral particles containing these vectors were generated by reverse transfection of these constructs with Trans-Lentiviral package mix, into HEK293T cells using Arrest-In/Express-In transfection reagent. A 1:1 dilution of virus produced was used to infect iGROV1 cells in the presence of polybrene (10 μg/ml) and stable cultures generated by growing in puromycin (1 μg/ml). FRA silencing was confirmed by RT-qPCR and folate binding assay.
FRA analysis and folate binding
RNA was extracted using RNeasy Plus Mini Kit (Qiagen). Reverse transcription was performed with 2 μg RNA using High-capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). QPCR was performed using ABsolute qPCR Mix (Thermo Scientific) with the following sense/ anti-sense oligonucleotide primers:
FRA Sense 5′-CAT TGC ACA GAA CAG TGG GTG-3′ Anti-sense 5′-AAG TGC GCA GTG GGA GCT-3′ GAPDH Sense 5′-ACA ACT TTG GTA TCG TGG AAG G-3′ Anti-sense 5′-CAG TAG AGG CAG GCA TGA TGT TC-3′
No RT controls were used to confirm lack of contaminating genomic DNA. FRA expression was determined using the following equation: 2Ct(reference) − Ct(target) with GAPDH as the reference gene.
Folate binding assays were performed as described [30] and modified [31] . Briefly, cells were plated at 2.5 × 10 5 cells/well in 24-well plates overnight in folate-free RPMI and 10% FBS containing ~ 0.02 μM physiological levels of folate (plating medium). Cells were placed on ice, washed twice with cold low pH buffer (20 mM sodium acetate; pH 3.0) to strip remaining folate from cell membrane and then washed two times in cold PBS (3 mM sodium phosphate, 155 mM NaCl, 1 mM potassium phosphate; pH 7.4) prior to incubation in 61 μCi/ml 3 H-folate (100 nM 
Synthesis of IgA Fc-folates
Fc fragments were generated from pooled human IgA (~ 80% IgA-1) using Pierce's Fab Preparation Kit (ThermoFisher Scientific) per their instructions. Briefly, immobilized papain resin (0.125 ml) was equilibrated in microspin columns with digestion buffer (PBS) and then incubated with 0.5 ml of whole IgA (1 mg/ml) in digestion buffer for 8 h with end-over-end rotation at 37 °C. After the desired timepoint, digest was separated from resin by centrifugation and the Fc fragment was affinity purified from the digest using Human IgA Affinity Matrix columns (Thermo Fisher Scientific) which contain antibody fragments recognizing all human IgA subclasses. The affinity resin (0.125 ml) was equilibrated in micro-spin columns with digestion buffer and then incubated with digest (0.5 ml) for 30 min with endover-end rotation at room temperature. Fc fragments retained on the resin were collected by centrifugation followed by four washes with PBS (0.5 ml) and eluting with 0.1 M glycine (pH 3). Fc fragment purity and yield were determined by SDS-PAGE analysis of both wash and elution fractions which should contain Fab and Fc fragments, respectively.
Folate was attached to whole IgA or Fc fragments by coupling folate to amine groups using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) to activate folate according to the manufacturer (Pierce). N-hydroxysuccinimide (NHS) was used to stabilize the acylisourea folate intermediate. Briefly, folic acid (1 mg/ml) in DMF and activation buffer (0.1 M MES, 0.5 M NaCl, pH 6.0) at a ratio of 1:1 were activated by adding EDC (10-fold molar excess) and NHS (2.5 molar excess to EDC) and incubating for 15 min at room temperature in the dark. After incubation, EDC was quenched by addition of 20 mM BME and IgA or Fc fragments in coupling buffer (100 mM sodium phosphate, 150 mM NaCl; pH 7.2) were added and allowed to incubate at room temperature for 2 h. The reaction was quenched by addition of hydroxylamine (10 mM) and excess activated folate removed using 7kD Zeba desalting spin columns (Thermo Scientific).
Fc-folate binding to FcαR1 and MPO release
Binding specificity of Fc-folate to FcαR1 was determined by cell-based ELISA assay. To do this, ELISA plates were triplicate coated overnight with IgA or Fc fragments, their corresponding folate conjugates, or bovine serum albumin (negative control) in PBS at varying doses. After incubation, unattached protein was washed away and freshly isolated and BCECF-labeled PMNs were added at 4 × 10 5 cells/well in plating medium and allowed to attach. After 30 min, wells were PBS washed and remaining PMNs detected by lysing in 2% SDS, transferring to black plates and measuring BCECF fluorescence (ex: 485/20 and em: 528/20) using a BioTek Synergy 2 plate reader. Values represent average absorbance per treatment. Functionality of folate conjugates binding to FcαR1 was determined by measuring PMN-induced MPO release. Briefly, plates were coated overnight as described above and freshly isolated and unlabeled PMNs were added and incubated for 6 h. After incubation, supernatants were removed, spun down to remove cellular debris and stored at − 80 °C until assayed. MPO was measured as previously described [29] . Briefly, 50 μl of the supernatant fluids containing MPO was incubated in 200 μl of a potassium phosphate buffer (50 mmol/L) containing the substrate, H 2 O 2 (1.5 mol/L) and o-dianisidine dihydrochloride (167 μg/ml; Sigma Aldrich). Enzyme activity rate was determined spectrophotometrically by measuring the change in absorbance at 460 nm over 10 min using a 96-well plate reader. Values represent the average maximum MPO activity (abs/sec).
51
Cr-release and calcein-AM cytotoxicity assays 51 Cr-release assays were performed as previously described [32] . Briefly, TNBC cells were plated at 1 × 10 5 cells/well in 96-well plates overnight in plating medium and then labeled with 51 Cr (250 μCi/ml) for 4 h. Excess 51 Cr was washed away with PBS and cells were incubated overnight (12-15 h) in co-culture with PMNs and in the presence and absence of Fc-folate (3 μM), treated in triplicate, at a target to effector ratio of 1:60 (T:E). Cell lysis was determined by measuring 51 Cr released into the supernatant using a PerkinElmer scintillation counter. For each cell line, resulting cpm values in the supernatant from control wells (TNBC cells with no PMNs) were subtracted from all PMN-containing wells. Results are expressed as percent of maximum control lysis where maximum control lysis of each cell line was determined by lysing additional control wells with 2% SDS.
Calcein-AM assays were performed according to the manufacturer's instructions (ThermoFisher Scientific). Briefly, TNBC cells were plated at 1 × 10 5 cells/well in 96-well black plates overnight in plating medium and then labeled with calcein-AM dye (1 mg/ml) for 45 min. Excess dye was washed away with PBS and cells were incubated for 8 h in co-culture with PMNs and in the presence and absence of Fc-folate (3 μM), treated in triplicate and at a target to effector ratio of 1:50 (T:
Statistical analyses
Data were analyzed using GraphPad Prism (v.7.0) for Macintosh. All results are expressed as mean ± SD of three independent experiments unless otherwise stated and statistical analysis performed by one-way or two-way repeated measures analysis of variance (ANOVA) followed by multiple comparison procedure with Student-Newman Keuls method. A value of P = 0.01 was considered significant.
Results
TNBC cells express FRA and bind folate
FRA expression was measured by RT-qPCR in various TNBC cells. All TNBC cells tested expressed varying levels of FRA except BT549 cells (Fig. 2a) . Folate binding assays utilizing 3 H-labeled folate as described above were performed with the high FRA-expressing cells (Fig. 2b) 
Binding of IgA-and Fc-folates to FRA
IgA and Fc-folate conjugates were synthesized as described above. Fc fragmentation was confirmed by gel electrophoresis (Fig. 3) showing a band around 30 kd in the elution fraction (Fc fragment) and lack of bands at 25 and 45 kd corresponding to Fab fragments present in high levels in the wash fraction (Fab fragment). The presence of heavy and light chains in the Fc fraction indicates incomplete digestion of IgA. Multiple attempts to achieve complete digestion were attempted without success so the digestion shown above was used for synthesis of the Fc-folate conjugate.
After synthesis, the folate concentration of the conjugates was determined spectrophotometrically at 363 nm and binding to FRA tested in the 3 H-folate binding assay. Resulting cpm values were plotted and amount of conjugate required to displace 50% of 3 H-folate bound to FRA on iGROV1s was determined. Both IgA and Fc-folate conjugates bound to FRA, displacing 100 nM 3 H-folate with IC50 values of 2.8 μM for whole IgA (Fig. 4a) . For Fc-folate conjugate, almost complete inhibition was achieved at the lowest concentration tested (0.724 μM). The lowest dose of Fc-folate found to achieve maximum 3 H-folate displacement (3 μM) was used to confirm specificity of 3 H-folate and Fc-folate for FRA (Fig. 4b) (Fig. 5) . After overnight coating of ELISA plates with varying concentrations of either whole IgA, Fc fragment, IgA-folate, or Fc-folate, pre-labeled PMNs were added to the plate for 30 min, washed to remove non-adherent PMNs, and remaining PMNs bound were determined by measuring BCECF fluorescence. In the presence of the lowest dose of Fc-folate (0.75 μg/ml), there was a slight but insignificant increase in PMN adherence (Fig. 5a) . However, at a dose of 1.56 μg/ml and above, both IgA and Fc fragments, as well as their corresponding folate conjugates, induced at least fourfold significant increase in PMN adherence compared to BSA treated wells with maximum adherence occurring at a dose of 3.125 μg/ml (Fig. 5a) .
Although it is unclear how PMNs mediate ADCC, studies have shown that MPO is essential for this process to occur [35] . Therefore, to test for functionality of the folate . Results represent the mean ± SD of n = 3 independent experiments performed in triplicate. b PMN-induced MPO release was measured in the clarified supernatant collected 6 h after plating of unlabeled PMNs in the ELISA experiment described in Part A. Results represent the mean ± SD of n = 3 independent experiments performed in triplicate where *P < 0.01 compared to samples containing PMN alone conjugates, their ability to induce PMNs to release MPO was determined using an ELISA plate coated overnight with both IgA and Fc fragments, as well as their corresponding folate conjugates as described above. Since initial studies showed significant IgA-induced MPO release by PMNs compared to BSA treated wells alone as early as 6 h after PMN addition, this timepoint was chosen to measure MPO release. Results demonstrate a dose-dependent increase in MPO release by PMNs exposed to both IgA fragment and its folate conjugate with a significant increase compared to BSA alone at a concentration of only 1.56 μg/ml (Fig. 5b) . A dose-dependent increase in MPO release was also triggered by Fc fragment or its folate conjugate but the response was slighter weaker with a small but significant increase at a concentration of 6.25 μg/ml. The response of the folate conjugates compared to their fragments alone was not significantly different in either the MPO or adhesion assay, demonstrating that attached folate has no effect on IgA or Fc fragment binding to FcαR1.
TNBC cells bind Fc-folate and trigger cell lysis
Once binding of the Fc fragment to FRA-expressing iGROV1 was established, ADCC by PMNs due to Fc-folate binding was tested in high FRA-expressing TNBC cells using both the standard chromium ( 51 Cr)-release assay [32] and fluorescent-based calcein-AM assay. First, their ability to inhibit binding of 3 H-folate to these cells was determined and results demonstrated a significant inhibitory effect of Fc-folate, at a concentration of 3 µM (Fig. 6a) . Using these same cell lines, in addition to iGROV1, ADCC was tested and results demonstrate a significant increase in cell lysis of all TNBC cells tested by the PMNs in the presence of Fc-folate compared to cells cultured with PMNs alone (Fig. 6b, c) . The iGROV1s were the most sensitive (100% lysis) which corresponds with their high FRA expression level (Fig. 2a) and lack of lysis in the shFRA-expressing iGROV1s by PMNs confirms FRA requirement. Interestingly, ADCC measured by the calcein-AM assay corresponded more closely with FRA expression in the TNBC cells compared to the 51 Cr release assay.
Discussion
Since identification and pioneering studies of FRA [36] [37] [38] [39] [40] , targeting FRA in ovarian and, recently, breast cancer with various cytotoxics is currently being tested in the clinic. Some of these are in Phase II/III trials for treatment of cancers [41] [42] [43] . However, the first Phase III clinical trial incorporating one of these drugs (Vintafolide) was recently halted for lack of efficacy compared to chemotherapy alone [44] and others trials suspended as well [45, 46] . [21] [22] [23] [24] [25] [26] [27] [28] as well as in vivo using IgA targeting EGFR antibodies [47, 48] . However, research into the therapeutic use of FcαR1 is hampered by lack of appropriate mouse models (because mice do not express FcαR1 [49] ) and lack of established models for production/ purification of high levels of IgA [50] . In this study, we demonstrate that an IgA Fc-folate conjugate can bind strongly to FRA receptors on TNBC stimulating PMN-mediated cell killing and thus avoids these obstacles because it utilizes only an Fc portion of IgA so there is no need to make IgA antibodies targeting FRA. We are in the process of developing homozygous BALB/c scid mice with the human FcaR1 gene inserted for in vivo testing of recombinant Fc-folate conjugates. Since PMNs are present in breast tumors at high levels and are cytotoxic towards tumor cells [51] , FcαR1 could be an ideal target for other drugs targeting PMN-triggered ADCC in TNBC. Since activation of ADCC through FcαR1 requires IgA complexes, [52] there is no toxicity due to binding of plasma monomeric IgA. The concept of utilizing IgA can be applied to other cancer immunotherapies as well as a means for improving efficacy or for treating autoimmune diseases.
The results of this study strongly support the hypothesis that IgA Fc-folate conjugates can effectively destroy TNBC cells by binding FRA and eliciting PMN-mediated ADCC.
Unlike other failed FRA-mediated approaches or those requiring internalization by tumor cells or dependence on an adaptive immune response which is defective in human tumors, Fc-folate conjugates only need to bind FRA to activate PMNs to effectively target TNBC tumors. By doing so, Fc-folates will decrease TNBC patient mortality and will do so with little toxicity because it will only target FRA-expressing tumor cells. Fc-folates can be applied to other aggressive FRA-expressing cancers including ovarian and lung, which also have high mortality rates. Cr (250 μCi/ml) for 4 h. Excess 51 Cr was washed away and cells were incubated overnight (12-15 h) in same medium and in co-culture with PMNs in the presence and absence of Fc-folate (3 μM) at a target-to-effector ratio of 1:60 (T:E). Cell lysis for each cell line was determined by measuring 51 Cr released into the supernatant. For each cell line, resulting cpm values in the supernatant from control wells (TNBC cells with no PMNs) were subtracted from all PMN-containing wells. Results are expressed as percent of maximum control lysis where maximum control lysis of each cell line was determined by lysing additional control wells with 2% SDS. Results represent mean ± SD of n = 2 experiments performed in triplicate where *P < 0.01 compared to samples containing PMN alone. c TNBC cells were plated at 1 × 10 5 cells/well in 96-well black plates overnight in low folate RPMI containing 10% FBS and then labeled with calcein-AM for 45 min. Excess dye was washed away with PBS and cells were incubated for 8 h in co-culture with PMN and in the presence and absence of Fc-folate (3 μM) at a target-to-effector ratio of 1:50 (T:E). After 8 h, wells were washed and remaining adherent cells were lysed with 2% SDS and detected by measuring calcein fluorescence (ex: 485/20 and em: 528/20). Cell viability for each cell line is expressed as percent of control where control represents the TNBC cells without PMN treatment. Results are the mean ± SEM of n = 3 independent experiments performed in triplicate where *P < 0.01 compared to samples containing PMN alone
